HUMAN INTERLEUKIN-2 VARIANT OR ITS DERIVATIVE Russian patent published in 2023 - IPC C07K14/55 C07K16/30 C07K19/00 C12P21/02 A61K38/20 A61K47/68 A61P35/00 A61P37/00 

FIELD: biotechnology.

SUBSTANCE: invention relates to the production of mutant variants and derivatives of human interleukin-2 (IL-2), and can be used in medicine for the treatment of a proliferative or autoimmune disease or diabetes, or the treatment or prevention of an autoimmune response due to organ transplantation. The proposed mutein contains mutations selected from the group consisting of 15)-17), or any of 15)-17) in combination with any of 5)-7): 15) N26Q and N29S, 16) N26Q, N29S and N71Q, and 17) N26Q and N30S, 5) Q11C and L132C, 6) L70C and P82C, and 7) G27C and F78C, and may contain additional mutations. A conjugate is proposed in which the IL-2 mutant variant is PEGylated and/or glycosylated and/or albumin-conjugated or albumin-fused and/or Fc-fused and/or hydroxyethylated. Also, the IL-2 mutant variant can be directly linked to the antigen binding module or indirectly linked to the antigen binding module via a peptide linker.

EFFECT: invention provides a variant of IL-2 and its derivative with increased stability compared to wild-type IL-2 and improved properties as an immunotherapeutic agent.

39 cl, 10 dwg, 22 tbl, 13 ex